Nature Medicine, Published online: 16 October 2026; doi:10.1038/s41591-026-04715-w
Results of a phase 1 trial of the antibody−toxin conjugate D2C7-ATC targeting EGFR/EGFRvIII in patients with recurrent malignant glioma show encouraging safety and efficacy signals, with translational analyses of patient samples indicating intratumoral and systemic immune activation.
